Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unimark Remdies, India, has changed its production pipeline to develop the active pharmaceutical ingredients (API), an anti-biotic amoxycillin through the biocatalysis process.
Subscribe to our email newsletter
The biocatalysis technology is a greener, cleaner, and more economic way to manufacture chiral drugs cutting the production costs by 25-30%.
The company has wound up the plans to manufacture Atorvastatin,an anti-cholesterol drug and Benezepril,an anti-hypertension drug in lieu of the market competition and approval terms of US Food and Drugs Administration(USFDA).
Instead Unimark has decided to develope the API for amoxycillin, an antibiotic,through the biocatalysis process.
Unimark Remedies executive director Sandip J Parekh was quoted by the Business Standard as saying that "DSM is the only international company that makes amoxycillin using the enzymes route, all others use the chemical process. We will have a major competitive edge over other producers, as through the biocatalysis route, we can offer the API at a much cheaper rate."
The company also plans to develop certain intermediates that go into anti-biotic production.